The US Department of Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD): A Biorepository Addressing National Health Threats.
COVID-19 sequence analysis
Veterans health
biological specimen banks
communicable diseases
data warehousing
government agencies
health policy
public health surveillance
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
14
09
2022
entrez:
5
1
2023
pubmed:
6
1
2023
medline:
6
1
2023
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans. In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities. VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities. VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide.
Sections du résumé
Background
UNASSIGNED
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans.
Methods
UNASSIGNED
In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities.
Results
UNASSIGNED
VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities.
Conclusions
UNASSIGNED
VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide.
Identifiants
pubmed: 36601554
doi: 10.1093/ofid/ofac641
pii: ofac641
pmc: PMC9801224
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac641Subventions
Organisme : BLRD VA
ID : I01 BX005428
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors have noo reported conflicts of interest.
Références
JAMA Netw Open. 2021 Nov 1;4(11):e2132548
pubmed: 34730819
PLoS One. 2022 Apr 25;17(4):e0266381
pubmed: 35468170
PLoS Genet. 2022 Apr 28;18(4):e1010113
pubmed: 35482673
JAMA Netw Open. 2020 Sep 1;3(9):e2022310
pubmed: 32965502
Front Genet. 2022 Feb 03;12:777076
pubmed: 35222515
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
J Clin Epidemiol. 2016 Feb;70:214-23
pubmed: 26441289
PLoS One. 2021 May 13;16(5):e0251651
pubmed: 33984066
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1294-1299
pubmed: 34529636
Front Public Health. 2021 Oct 29;9:739076
pubmed: 34778173
Appl Transl Genom. 2014 Apr 12;3(2):30-5
pubmed: 27275411
JAMA Intern Med. 2022 Apr 01;182(4):386-395
pubmed: 35089317